Clinical outcomes of first antiretroviral regimen in HIV/hepatitis C virus co-infection

HIV Medicine

Volumn 7, Issue 1, 2006, Pages 32-37

  Cooper, C L ^a   Breau, C ^a   LaRoche, A ^a   Lee, C ^a   Garber, G ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

Author keywords

HAART; HCV; Liver

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIRETROVIRUS AGENT; ASPARTATE AMINOTRANSFERASE; EFAVIRENZ; LAMIVUDINE; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; VIRUS RNA; ZIDOVUDINE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASCITES; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CD4 LYMPHOCYTE COUNT; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG CHOICE; DRUG DOSE REGIMEN; DRUG POTENCY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL TOXICITY; HEPATITIS C; HEPATITIS C VIRUS; HEPATOMEGALY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; LIVER TOXICITY; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; METABOLIC DISORDER; NEUROLOGIC DISEASE; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; SEX DIFFERENCE; SUBSTANCE ABUSE; SUPERINFECTION; TREATMENT DURATION; TREATMENT OUTCOME; VIRUS INHIBITION; VIRUS LOAD;

ADULT; ALANINE TRANSAMINASE; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ASPARTATE AMINOTRANSFERASES; BIOLOGICAL MARKERS; CD4 LYMPHOCYTE COUNT; DRUG ADMINISTRATION SCHEDULE; FEMALE; GASTROINTESTINAL DISEASES; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; LIVER DISEASES; MALE; MIDDLE AGED; PATIENT COMPLIANCE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VIRAL LOAD;

EID: 33645969285     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2005.00340.x     Document Type: Article

References (18)

1. Sherman KE, Roustrer S, Chung R, Rajicic N. Hepatitis C prevalence in HIV-infected patients: A cross-sectional analysis of the US ACTG. Antivir Ther 2000; 5 (Suppl. 1): 64-65.
2. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001; 345: 41-52.
3. Benhamou Y, Di Martino V, Bochet M et al. Factors affecting liver fibrosis in human immunodeficiency virus- and hepatitis C virus-coinfected patients: Impact of protease inhibitor therapy. Hepatology 2001; 34: 283-287.
4. Benhamou Y, Bochet M, Di Martino V et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology 1999; 30: 1054-1058.
5. Rosenthal E, Poiree M, Pradier C et al. Mortality due to hepatitis C-related liver disease in HIV-infected patients in France (Mortavic 2001 study). AIDS 2003; 17: 1803-1809.
6. Qurishi N, Kreuzberg C, Luchters G et al. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet 2003; 362: 1708-1713.
7. Perronne C, Carrat F, Bani-Sadr F et al. Final results of ANRS HCO2-RIBAVIC: A randomized controlled trial of pegylated-interferon-a-2b plus Ribavirin vs interferon-a-2b plus Ribavirin for the initial treatment of chronic hepatitis in HIV co-infected patients. 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, February 2004 [Abstract 117LB].
8. Torriani FJ, Rockstroh J, Rodriguez-Torres M et al. Final results of APRICOT: A randomized, partially blinded, international trial evaluating peginterferon-a-2 + Ribavirin vs interferon-a-2a + Ribavirin in the treatment of HCV in HIV/HCV co-infection. 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, February 2004 [Abstract 112].
9. Chung R, Andersen J, Volberding P et al. A randomized, controlled trial of PEG-interferon-a-2a + Ribavirin vs Interferon-a-2a + Ribavirin for chronic hepatitis C virus infection in HIV-co-infected persons: Follow-up results of ACTG A5071. 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, February 2004 [Abstract 110].
10. Puoti M, Torti C, Ripamonti D et al. Severe hepatotoxicity during combination antiretroviral treatment: Incidence, liver histology, and outcome. J Acquir Immune Defic Syndr 2003; 32: 259-267.
11. Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. J Am Med Assoc 2000; 283: 74-80.
12. Nunez M, Lana R, Mendoza JL, Martin-Carbonero L, Soriano V. Risk factors for severe hepatic injury after introduction of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2001; 27: 426-431.
13. John M, Flexman J, French MA. Hepatitis C virus-associated hepatitis following treatment of HIV- infected patients with HIV protease inhibitors: An immune restoration disease? AIDS 1998; 12: 2289-2293.
14. Cooper CL, Parbhakar MA, Angel JB. Hepatotoxicity associated with antiretroviral therapy containing dual versus single protease inhibitors in individuals coinfected with hepatitis C virus and human immunodeficiency virus. Clin Infect Dis 2002; 34: 1259-1263.
15. Lucas GM, Cheever LW, Chaisson RE, Moore RD. Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection. J Acquir Immune Defic Syndr 2001; 27: 251-259.
16. Bangsberg DR, Hecht FM, Charlebois ED et al. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS 2000; 14: 357-366.
17. Klein MB, Willemot P, Murphy T, Lalonde RG. The impact of initial highly active antiretroviral therapy on future treatment sequences in HIV infection. AIDS 2004; 18: 1895-1904.
18. Panel on Clinical Practices for Treatment of HIV Infection convened by the Department of Health and Human Services. Guidelines for the Use of Antiretroviral Agents in HIV-1 Infected Adults and Adolescents. Department of Health and Human Services, Washington, DC, 2003.